American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

Neurocrine Biosciences Inc

NBIX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

NBIX historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of NBIX by members of U.S. Congress

Politician Type Traded
Lisa C. McClain House / R Sale $1,001 - $15,000 Jun 17, 2025
Lisa C. McClain House / R Purchase $1,001 - $15,000 Jun 11, 2025
Michael T. McCaul House / R Sale $15,001 - $50,000 Nov 19, 2024
Michael T. McCaul House / R Sale $15,001 - $50,000 Nov 19, 2024
Michael T. McCaul House / R Sale $1,001 - $15,000 N/A
Michael T. McCaul House / R Sale $1,001 - $15,000 Aug 26, 2024
Michael T. McCaul House / R Sale $50,001 - $100,000 Oct 27, 2023
Michael T. McCaul House / R Sale $15,001 - $50,000 Oct 27, 2023
Michael T. McCaul House / R Purchase $50,001 - $100,000 Aug 14, 2023
Michael T. McCaul House / R Purchase $15,001 - $50,000 Aug 14, 2023
Michael T. McCaul House / R Sale $15,001 - $50,000 May 02, 2023
Michael T. McCaul House / R Sale $15,001 - $50,000 May 02, 2023
Ro Khanna House / D Sale $1,001 - $15,000 Feb 10, 2023
Michael T. McCaul House / R Sale $1,001 - $15,000 Dec 16, 2022
Michael T. McCaul House / R Sale $1,001 - $15,000 Dec 16, 2022
Ro Khanna House / D Purchase $1,001 - $15,000 Dec 06, 2022
Michael T. McCaul House / R Sale $1,001 - $15,000 Jan 28, 2022
Michael T. McCaul House / R Sale $1,001 - $15,000 Jan 28, 2022
Michael T. McCaul House / R Sale $15,001 - $50,000 Dec 21, 2021
Michael T. McCaul House / R Sale $15,001 - $50,000 Dec 21, 2021
Michael T. McCaul House / R Sale $1,001 - $15,000 Dec 14, 2021
Michael T. McCaul House / R Sale $1,001 - $15,000 Dec 14, 2021
Michael T. McCaul House / R Purchase $15,001 - $50,000 Jun 24, 2021
Michael T. McCaul House / R Purchase $15,001 - $50,000 Jun 24, 2021
Michael T. McCaul House / R Purchase $15,001 - $50,000 Mar 09, 2021
Michael T. McCaul House / R Purchase $15,001 - $50,000 Mar 09, 2021
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Dec 21, 2020
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Michael T. McCaul House / R Purchase $50,001 - $100,000 Nov 12, 2020
Michael T. McCaul House / R Purchase $50,001 - $100,000 Nov 12, 2020
Michael T. McCaul House / R Sale $50,001 - $100,000 Oct 01, 2020
Michael T. McCaul House / R Sale $50,001 - $100,000 Oct 01, 2020
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Jul 21, 2020
Michael T. McCaul House / R Purchase $15,001 - $50,000 Mar 02, 2020
Michael T. McCaul House / R Sale $1,001 - $15,000 Dec 12, 2019
Michael T. McCaul House / R Sale $1,001 - $15,000 Dec 12, 2019
Michael T. McCaul House / R Purchase $15,001 - $50,000 Jan 18, 2019
Michael T. McCaul House / R Purchase $15,001 - $50,000 Jan 17, 2019
Michael T. McCaul House / R Purchase $15,001 - $50,000 Jan 16, 2019
Michael T. McCaul House / R Purchase $15,001 - $50,000 Jan 15, 2019
Ro Khanna House / D Sale $1,001 - $15,000 Dec 17, 2018
Josh Gottheimer House / D Sale $1,001 - $15,000 Dec 13, 2018
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 03, 2018
NBIX Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
NBIX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
NBIX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in NBIX holdings by institutional investors

Insider Trading

Quarterly net insider trading by NBIX's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $940,000 Jul 20, 2026 Issue: Medicare/Medicaid Health Issues Budget/Appropriations Taxation/Internal Revenue Code
  • $940,000 Apr 20, 2026 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Budget/Appropriations
  • $900,000 Jan 20, 2026 Issue: Medicare/Medicaid Health Issues Budget/Appropriations Taxation/Internal Revenue Code
  • $900,000 Oct 20, 2025 Issue: Medicare/Medicaid Health Issues Budget/Appropriations Taxation/Internal Revenue Code
  • $890,000 Jul 21, 2025 Issue: Medicare/Medicaid Health Issues Budget/Appropriations Taxation/Internal Revenue Code
  • $910,000 Apr 21, 2025 Issue: Medicare/Medicaid Health Issues Budget/Appropriations Taxation/Internal Revenue Code
  • $830,000 Jan 21, 2025 Issue: Medicare/Medicaid Health Issues Budget/Appropriations Taxation/Internal Revenue Code
  • $830,000 Oct 21, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $830,000 Jul 22, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $780,000 Jan 22, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $780,000 Oct 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $780,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $700,000 Jan 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $790,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $790,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $900,000 Jun 13, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $730,000 Jun 13, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Health Issues Medicare/Medicaid
  • $720,000 Oct 20, 2021 Issue: None
  • $700,000 Jul 20, 2021 Issue: None
  • $590,000 Apr 20, 2021 Issue: None
  • $820,000 Jan 19, 2021 Issue: None
  • $480,000 Oct 19, 2020 Issue: None
  • $440,000 Jul 20, 2020 Issue: None
  • $440,000 Apr 20, 2020 Issue: None
  • $640,000 Jan 21, 2020 Issue: None
  • $60,000 Oct 21, 2019 Issue: Pharmacy
  • $60,000 Jul 22, 2019 Issue: Pharmacy
  • $60,000 Apr 22, 2019 Issue: Pharmacy
  • $60,000 Jan 22, 2019 Issue: Pharmacy
  • $60,000 Oct 22, 2018 Issue: Pharmacy
  • $60,000 Jul 20, 2018 Issue: Pharmacy
  • $60,000 Apr 20, 2018 Issue: Pharmacy
  • $60,000 Jan 22, 2018 Issue: Pharmacy
  • $60,000 Oct 20, 2017 Issue: Pharmacy
  • $60,000 Jul 20, 2017 Issue: Pharmacy
  • $10,000 Apr 24, 2017 Issue: Pharmacy
Revolving Door

Former government officials who have lobbied for NBIX

37 former government officials from 26 congressional offices at 5 lobbying firms have lobbied for NBIX, most recently Jul 20, 2026.

  • Tom Bliley
    Brent Del Monte House Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee Formerly with Tom Bliley · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Bill Cassidy
    Robb Walton Senate Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Research Asst., Staff Asst., Intern on Senate HELP, Ranking Member, Sen. Enzi; Intern to Rep. Nunes Formerly with Bill Cassidy · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • John Stone House Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C Formerly Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Elizabeth Warren
    Remy Mason Senate Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz Formerly with Elizabeth Warren · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Debbie Wasserman Schultz
    Daniel Farmer House Intern, Staff Asst, Leg. Corr./Leg. Asst. for Rep. Debbie Wasserman Schultz; Leg. Asst., Sr. Leg. Asst., Leg. Dir. for Zack Space Formerly with Debbie Wasserman Schultz · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Scott L. Klug
    Robert Wood House Chief of Staff to HHS Secretary; Intern to Rep. Scott Klug Formerly with Scott L. Klug · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Jimmy Panetta
    Joel Bailey House COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Rep. Matsui; LA, Sr. LA Rep. Baron Hill; Intern Rep. Rahall Formerly with Jimmy Panetta · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
  • Ron Wyden
    Raghav Aggarwal Senate Health Insurance Specialist, CMS; Senior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron Wyden; Social Science Research Analyst, CMS; Intern, Sen. Feinstein; Secretarys Fellow, US Dept. of Interior Formerly with Ron Wyden · BGR GOVERNMENT AFFAIRS · Jul 20, 2026
See all 37 on the Revolving Door dashboard
Corporate Lobbying

NBIX Estimated quarterly lobbying spending

Revenue Breakdown

NBIX Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
NBIX Income Statement
NBIX Balance Sheet
NBIX Cash Flow
U.S. Patents

New NBIX patent grants

  • Patent Title: Substituted pyrazolo[1,5-α]pyrimidines as crf receptor antagonists Jul. 21, 2026
  • Patent Title: Substituted pyrido[2,1-a]isoquinolines as vmat2 inhibitors Jun. 09, 2026
  • Patent Title: Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine Mar. 24, 2026
  • Patent Title: Muscarinic receptor 4 antagonists and methods of use Dec. 02, 2025
  • Patent Title: Gpr52 modulators and methods of use Sep. 23, 2025
  • Patent Title: Crf receptor antagonists and methods of use Aug. 12, 2025
  • Patent Title: Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine Oct. 29, 2024
  • Patent Title: Treatment of congenital adrenal hyperplasia Aug. 22, 2023
  • Patent Title: Substituted pyrido[2,1-a]isoquinolines as vmat2 inhibitors Aug. 08, 2023
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Aug. 01, 2023
  • Patent Title: Methods for the administration of certain vmat2 inhibitors May. 23, 2023
  • Patent Title: Processes for the preparation of uracil derivatives Oct. 04, 2022
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Sep. 13, 2022
  • Patent Title: Treatment of congenital adrenal hyperplasia Apr. 26, 2022
  • Patent Title: High dosage valbenazine formulation and compositions, methods, and kits related thereto Apr. 26, 2022
  • Patent Title: [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto Jul. 06, 2021
  • Patent Title: Vmat2 inhibitor compounds and compositions thereof Jun. 22, 2021
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Jun. 22, 2021
  • Patent Title: Compounds of formulas (vii), (viii), (ix), (xi), (xii), (xiii), and (xiv) as muscarinic receptor 4(m4) antagonists for treating neurological diseases Jun. 15, 2021
  • Patent Title: High dosage valbenazine formulation and compositions, methods, and kits related thereto Jun. 08, 2021
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Jun. 08, 2021
  • Patent Title: Substituted triazoles and methods relating thereto Jun. 01, 2021
  • Patent Title: Methods for the administration of certain vmat2 inhibitors May. 04, 2021
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Mar. 23, 2021
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Mar. 09, 2021
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Mar. 09, 2021
  • Patent Title: Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Feb. 16, 2021
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Feb. 09, 2021
  • Patent Title: Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Feb. 02, 2021
  • Patent Title: Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Feb. 02, 2021
  • Patent Title: Treatment of congenital adrenal hyperplasia Feb. 02, 2021
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Dec. 29, 2020
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Dec. 08, 2020
  • Patent Title: Methods for the administration of certain vmat2 inhibitors Dec. 08, 2020
  • Patent Title: Valbenazine salts and polymorphs thereof Dec. 01, 2020
  • Patent Title: [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto Jun. 05, 2018
  • Patent Title: Processes for the preparation of uracil derivatives Jan. 16, 2018
  • Patent Title: Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof Oct. 10, 2017
  • Patent Title: Substituted triazoles and methods relating thereto Aug. 01, 2017
  • Patent Title: [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto Jul. 25, 2017
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Aug. 23, 2016
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Feb. 10, 2015
  • Patent Title: Processes for the preparation of uracil derivatives Jul. 01, 2014
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Aug. 13, 2013
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Jul. 09, 2013
  • Patent Title: Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto Jan. 22, 2013
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Sep. 11, 2012
  • Patent Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Dec. 27, 2011
  • Patent Title: Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto Oct. 18, 2011
  • Patent Title: Crf receptor antagonists and methods relating thereto Jan. 26, 2010
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to NBIX from public contracts

NBIX News

Recent insights relating to NBIX

CNBC Recommendations

Recent picks made for NBIX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in NBIX

NBIX Analyst Ratings

NBIX Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
NBIX Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $NBIX stock a Buy, Sell, or Hold?

  • What is the price target for $NBIX stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

NBIX Top Shareholders
Shareholder
Shares Held
NBIX Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $NBIX stock?

  • Who owns the most shares of $NBIX stock?

  • What funds own $NBIX stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

NBIX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view NBIX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About NBIX

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

  • Address San Diego, CA
  • Market Cap 14.5 billion
  • Employees 2,500
  • Industrial Classification Biological Products, (No Diagnostic Substances)

Neurocrine Biosciences Inc (NBIX) Historical Stock Prices

Neurocrine Biosciences Inc (NBIX) closed at $142.25 on September 22, 2026. Over the past year its adjusted close ranged from $123.10 to $185.50. Daily prices go back to January 2, 2014, 3,199 trading days in all.

  • 1 month-6.76%
  • 3 months-11.89%
  • Year to date+0.30%
  • 1 year-2.98%
  • 3 years+25.07%
  • 5 years+49.66%
  • Max+1,389.53%
See every congressional and insider trade on the NBIX price chart

Quiver Premium charts NBIX's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 22, 2026 144.17 144.26 141.78 142.25 142.25 1,213,787
Sep 21, 2026 146.15 146.26 143.45 143.96 143.96 1,385,320
Sep 18, 2026 152.63 152.63 146.06 146.23 146.23 2,816,257
Sep 17, 2026 151.14 152.06 149.71 151.83 151.83 1,178,348
Sep 16, 2026 150.34 151.31 149.00 149.50 149.50 1,015,821
Sep 15, 2026 156.70 156.70 149.15 150.02 150.02 1,332,180
Sep 14, 2026 158.00 159.19 156.57 157.22 157.22 785,561
Sep 11, 2026 157.19 159.67 156.12 156.22 156.22 890,877
Sep 10, 2026 154.38 159.94 152.04 156.57 156.57 895,198
Sep 9, 2026 154.61 155.55 152.38 155.14 155.14 1,050,719
Sep 8, 2026 153.99 156.82 151.77 155.13 155.13 820,810
Sep 4, 2026 158.24 159.80 154.83 155.64 155.64 933,569
Sep 3, 2026 159.93 159.93 156.76 158.35 158.35 758,262
Sep 2, 2026 157.39 160.43 155.09 157.79 157.79 1,037,887
Sep 1, 2026 154.31 157.03 153.70 156.76 156.76 878,438
Aug 31, 2026 153.11 155.00 151.77 154.03 154.03 1,741,100
Aug 28, 2026 155.92 156.57 153.08 154.06 154.06 812,988
Aug 27, 2026 155.28 156.75 154.61 155.92 155.92 730,293
Aug 26, 2026 153.21 159.40 152.02 156.59 156.59 1,119,203
Aug 25, 2026 153.84 156.13 152.00 153.37 153.37 1,041,866
Aug 24, 2026 152.57 154.56 151.77 153.04 153.04 1,207,968
Aug 21, 2026 153.13 155.26 152.51 152.57 152.57 1,227,625
Aug 20, 2026 154.99 155.81 152.50 152.93 152.93 870,659
Aug 19, 2026 156.56 156.56 154.34 155.54 155.54 1,162,825
Aug 18, 2026 155.92 156.24 153.46 154.23 154.23 1,037,564
Aug 17, 2026 151.62 154.81 150.69 154.49 154.49 1,168,987
Aug 14, 2026 149.72 153.42 148.78 152.72 152.72 1,305,198
Aug 13, 2026 154.43 155.81 150.20 150.82 150.82 2,055,841
Aug 12, 2026 159.74 159.98 154.86 156.49 156.49 2,094,377
Aug 11, 2026 165.46 165.46 161.78 161.94 161.94 808,120
Aug 10, 2026 161.52 165.15 161.52 164.92 164.92 935,226
Aug 7, 2026 161.53 164.76 159.68 163.41 163.41 971,005
Aug 6, 2026 161.28 162.51 158.47 159.82 159.82 1,366,423
Aug 5, 2026 168.55 168.55 161.30 161.50 161.50 1,292,449
Aug 4, 2026 166.89 169.01 165.71 166.06 166.06 1,197,253
Aug 3, 2026 166.25 170.88 164.01 166.23 166.23 1,515,976
Jul 31, 2026 184.34 185.55 164.56 166.80 166.80 4,584,499
Jul 30, 2026 179.00 186.12 176.60 185.50 185.50 2,171,768
Jul 29, 2026 182.00 183.50 180.00 180.79 180.79 1,072,183
Jul 28, 2026 178.84 182.91 176.25 182.83 182.83 1,333,544
Jul 27, 2026 176.46 179.15 176.00 176.41 176.41 1,047,908
Jul 24, 2026 174.25 177.30 173.43 175.77 175.77 1,129,509
Jul 23, 2026 170.67 174.99 170.00 174.15 174.15 1,103,193
Jul 22, 2026 178.87 181.00 171.81 172.69 172.69 1,192,294
Jul 21, 2026 174.77 179.05 174.10 179.05 179.05 1,305,466
Jul 20, 2026 172.37 174.59 171.70 173.00 173.00 977,544
Jul 17, 2026 169.77 172.57 169.26 170.88 170.88 929,824
Jul 16, 2026 170.78 172.62 169.01 171.55 171.55 900,946
Jul 15, 2026 172.04 173.12 169.44 172.05 172.05 878,503
Jul 14, 2026 177.33 177.33 169.04 172.04 172.04 1,054,074
Jul 13, 2026 174.50 175.88 172.03 174.10 174.10 1,573,201
Jul 10, 2026 181.00 181.18 174.21 177.11 177.11 1,047,443
Jul 9, 2026 178.52 181.00 177.65 180.55 180.55 1,178,634
Jul 8, 2026 177.70 178.62 175.28 178.24 178.24 1,155,802
Jul 7, 2026 176.10 178.75 174.75 177.49 177.49 1,033,826
Jul 6, 2026 175.01 175.02 171.14 174.10 174.10 922,907
Jul 2, 2026 169.10 174.38 168.26 174.26 174.26 1,251,145
Jul 1, 2026 169.50 169.56 165.91 167.77 167.77 927,447
Jun 30, 2026 170.66 171.50 168.24 168.53 168.53 1,075,813
Jun 29, 2026 168.87 171.43 167.90 170.00 170.00 1,350,842
Jun 26, 2026 163.59 169.56 163.12 168.52 168.52 1,953,260
Jun 25, 2026 165.84 168.07 163.68 164.18 164.18 783,664
Jun 24, 2026 163.43 168.58 162.34 166.06 166.06 1,362,010
Jun 23, 2026 161.62 163.53 160.42 161.44 161.44 1,076,140
Jun 22, 2026 161.17 161.79 159.32 161.62 161.62 1,008,894
Jun 18, 2026 160.01 161.33 156.31 158.29 158.29 2,718,236
Jun 17, 2026 156.62 160.02 155.66 159.00 159.00 1,037,812
Jun 16, 2026 160.61 161.66 155.30 156.42 156.42 934,446
Jun 15, 2026 159.89 160.55 156.70 159.51 159.51 1,243,782
Jun 12, 2026 162.04 162.97 159.44 159.76 159.76 1,055,122
Jun 11, 2026 161.59 164.04 160.18 162.71 162.71 764,864
Jun 10, 2026 167.80 169.39 160.72 160.86 160.86 1,097,249
Jun 9, 2026 164.89 166.43 160.88 165.24 165.24 1,098,906
Jun 8, 2026 163.88 165.40 162.22 163.12 163.12 804,519
Jun 5, 2026 167.53 168.00 163.11 163.88 163.88 1,050,184
Jun 4, 2026 165.23 169.57 164.52 167.35 167.35 1,301,800
Jun 3, 2026 155.56 165.81 155.12 165.11 165.11 1,942,029
Jun 2, 2026 160.40 160.40 154.06 154.84 154.84 1,039,480
Jun 1, 2026 159.36 161.80 157.44 161.00 161.00 1,220,835
May 29, 2026 156.71 159.08 155.43 158.30 158.30 1,907,857
May 28, 2026 155.75 157.84 154.32 156.39 156.39 1,068,490
May 27, 2026 156.74 157.62 154.48 155.83 155.83 708,583
May 26, 2026 158.00 158.25 155.66 155.73 155.73 984,355
May 22, 2026 156.95 158.63 155.44 156.70 156.70 758,794
May 21, 2026 153.74 157.26 152.54 155.50 155.50 1,037,007
May 20, 2026 154.80 156.48 152.56 154.67 154.67 1,168,560
May 19, 2026 156.59 156.88 153.27 154.36 154.36 1,386,480
May 18, 2026 158.70 159.76 156.09 157.21 157.21 1,127,634
May 15, 2026 158.22 159.23 155.50 158.42 158.42 1,307,348
May 14, 2026 161.62 162.39 157.60 159.05 159.05 1,285,158
May 13, 2026 157.95 161.76 155.77 161.32 161.32 1,565,297
May 12, 2026 151.43 156.32 150.82 155.80 155.80 1,309,694
May 11, 2026 152.00 154.44 150.32 150.59 150.59 1,216,875
May 8, 2026 150.00 154.74 149.54 152.25 152.25 1,414,990
May 7, 2026 146.10 150.36 146.08 149.59 149.59 1,790,205
May 6, 2026 148.98 148.98 141.96 147.02 147.02 2,437,274
May 5, 2026 135.00 137.15 132.76 135.06 135.06 1,427,489
May 4, 2026 131.78 134.66 131.78 134.07 134.07 1,196,434
May 1, 2026 131.79 132.41 129.86 131.78 131.78 680,075
Apr 30, 2026 132.04 134.11 129.75 131.67 131.67 966,477
Apr 29, 2026 126.48 131.36 126.48 131.23 131.23 1,708,727
Apr 28, 2026 129.18 130.41 127.22 128.12 128.12 844,615
Apr 27, 2026 127.43 129.46 126.99 128.04 128.04 1,500,590
Apr 24, 2026 130.00 130.34 127.20 127.68 127.68 1,203,054
Apr 23, 2026 131.18 132.48 129.30 130.19 130.19 518,727
Apr 22, 2026 131.25 131.43 129.89 131.18 131.18 753,445
Apr 21, 2026 131.65 132.78 129.56 130.22 130.22 933,039
Apr 20, 2026 132.89 134.11 130.33 131.59 131.59 1,775,794
Apr 17, 2026 129.00 133.74 128.41 133.25 133.25 1,728,446
Apr 16, 2026 131.00 131.71 127.76 128.41 128.41 1,030,447
Apr 15, 2026 131.96 132.14 130.46 131.44 131.44 1,098,535
Apr 14, 2026 126.32 130.84 126.32 130.81 130.81 1,113,939
Apr 13, 2026 128.69 129.41 125.64 126.32 126.32 1,093,608
Apr 10, 2026 132.02 133.00 127.17 128.89 128.89 806,992
Apr 9, 2026 132.75 133.17 130.15 131.64 131.64 820,305
Apr 8, 2026 131.18 133.20 128.90 133.15 133.15 1,216,019
Apr 7, 2026 133.35 134.20 128.99 130.90 130.90 1,772,053
Apr 6, 2026 130.93 134.01 125.31 132.48 132.48 2,021,482
Apr 2, 2026 130.81 133.75 130.00 131.60 131.60 706,966
Apr 1, 2026 131.93 133.40 130.25 132.56 132.56 1,133,043
Mar 31, 2026 131.74 133.99 129.97 131.74 131.74 1,339,187
Mar 30, 2026 129.48 130.10 128.20 128.72 128.72 740,577
Mar 27, 2026 132.07 132.95 128.02 128.32 128.32 761,337
Mar 26, 2026 131.13 133.01 129.96 132.42 132.42 574,610
Mar 25, 2026 128.98 133.04 128.98 131.13 131.13 1,099,232
Mar 24, 2026 126.14 128.31 125.11 127.86 127.86 1,293,058
Mar 23, 2026 129.65 130.97 127.03 127.05 127.05 709,804
Mar 20, 2026 128.83 130.16 126.68 127.68 127.68 2,182,008
Mar 19, 2026 130.62 132.25 127.07 129.70 129.70 892,311
Mar 18, 2026 129.95 131.05 129.01 130.71 130.71 800,601
Mar 17, 2026 130.14 131.69 129.88 130.71 130.71 632,395
Mar 16, 2026 130.40 131.89 129.48 129.85 129.85 915,184
Mar 13, 2026 128.64 130.72 128.05 129.78 129.78 947,832
Mar 12, 2026 129.51 130.00 127.15 127.78 127.78 793,333
Mar 11, 2026 129.86 130.55 128.10 129.54 129.54 780,669
Mar 10, 2026 130.42 131.90 129.07 129.86 129.86 799,380
Mar 9, 2026 128.43 130.13 126.88 129.93 129.93 855,662
Mar 6, 2026 128.33 129.25 126.95 128.13 128.13 903,626
Mar 5, 2026 132.04 133.00 129.22 129.64 129.64 1,560,222
Mar 4, 2026 131.33 134.83 131.01 133.44 133.44 1,379,623
Mar 3, 2026 131.99 132.41 128.00 131.14 131.14 889,213
Mar 2, 2026 130.32 133.25 130.32 132.38 132.38 1,025,240
Feb 27, 2026 129.12 132.99 129.09 132.25 132.25 1,321,823
Feb 26, 2026 131.24 132.19 128.93 130.64 130.64 833,284
Feb 25, 2026 132.00 132.25 130.02 131.15 131.15 919,168
Feb 24, 2026 129.09 131.38 128.03 130.96 130.96 990,967
Feb 23, 2026 128.02 128.79 126.59 128.38 128.38 1,025,396
Feb 20, 2026 129.45 130.34 127.16 128.63 128.63 1,080,171
Feb 19, 2026 128.89 130.98 127.78 130.10 130.10 1,244,922
Feb 18, 2026 127.13 128.87 126.02 128.38 128.38 1,091,067
Feb 17, 2026 125.14 129.94 125.14 127.76 127.76 1,609,469
Feb 13, 2026 123.83 126.50 123.36 124.12 124.12 2,202,770
Feb 12, 2026 132.34 134.50 122.14 123.10 123.10 4,166,745
Feb 11, 2026 136.99 139.83 135.02 137.44 137.44 1,388,509
Feb 10, 2026 140.34 142.82 137.56 137.65 137.65 1,322,725
Feb 9, 2026 141.02 141.09 138.50 139.56 139.56 870,144
Feb 6, 2026 138.75 142.15 138.27 141.20 141.20 1,154,003
Feb 5, 2026 136.46 141.45 136.46 137.93 137.93 1,272,936
Feb 4, 2026 139.07 140.43 137.03 137.86 137.86 935,665
Feb 3, 2026 137.04 141.24 137.04 138.98 138.98 996,884
Feb 2, 2026 135.33 137.95 135.00 137.63 137.63 940,405
Jan 30, 2026 136.63 137.95 134.96 136.06 136.06 1,035,473
Jan 29, 2026 135.53 138.12 133.41 137.96 137.96 928,519
Jan 28, 2026 133.01 137.45 132.75 134.66 134.66 934,771
Jan 27, 2026 134.50 136.51 133.54 133.89 133.89 582,367
Jan 26, 2026 134.36 136.21 134.11 134.51 134.51 925,271
Jan 23, 2026 138.16 138.74 135.41 136.18 136.18 1,159,677
Jan 22, 2026 135.57 137.73 134.94 137.37 137.37 800,575
Jan 21, 2026 135.34 136.19 133.72 135.41 135.41 927,324
Jan 20, 2026 130.22 134.77 129.17 134.54 134.54 1,057,080
Jan 16, 2026 133.31 134.02 131.36 132.39 132.39 1,023,440
Jan 15, 2026 135.24 135.98 131.30 133.35 133.35 890,953
Jan 14, 2026 132.17 135.48 132.01 135.33 135.33 1,078,923
Jan 13, 2026 133.20 133.78 131.33 132.26 132.26 1,161,230
Jan 12, 2026 135.21 135.54 132.16 132.66 132.66 1,923,043
Jan 9, 2026 135.99 137.07 134.87 135.79 135.79 1,419,297
Jan 8, 2026 139.54 139.68 134.20 135.57 135.57 1,568,583
Jan 7, 2026 138.03 142.16 137.60 140.62 140.62 1,289,088
Jan 6, 2026 136.77 138.53 135.95 137.35 137.35 1,118,400
Jan 5, 2026 136.00 138.18 134.03 135.99 135.99 1,614,579
Jan 2, 2026 141.59 142.07 138.64 140.60 140.60 963,710
Dec 31, 2025 140.63 142.30 140.50 141.83 141.83 849,233
Dec 30, 2025 143.03 143.18 140.56 140.95 140.95 1,000,445
Dec 29, 2025 145.26 145.51 143.26 143.64 143.64 696,205
Dec 26, 2025 146.27 146.78 144.65 145.26 145.26 693,794
Dec 24, 2025 148.17 148.38 146.53 146.93 146.93 359,676
Dec 23, 2025 146.42 148.56 146.42 147.28 147.28 550,029
Dec 22, 2025 145.00 148.45 145.00 147.53 147.53 694,661
Dec 19, 2025 142.97 145.95 141.00 145.00 145.00 1,983,725
Dec 18, 2025 141.78 144.23 141.23 141.84 141.84 1,520,865
Dec 17, 2025 150.47 150.47 141.61 141.70 141.70 1,758,151
Dec 16, 2025 155.23 155.23 148.03 148.74 148.74 1,012,623
Dec 15, 2025 152.78 155.55 151.12 154.06 154.06 768,198
Dec 12, 2025 155.00 155.29 151.09 152.80 152.80 948,912
Dec 11, 2025 153.39 156.46 153.30 154.75 154.75 1,037,814
Dec 10, 2025 155.87 156.69 151.59 155.63 155.63 948,918
Dec 9, 2025 153.45 156.27 152.29 155.02 155.02 836,708
Dec 8, 2025 156.65 160.18 154.74 154.99 154.99 1,432,063
Dec 5, 2025 154.47 156.76 153.38 155.51 155.51 893,211
Dec 4, 2025 152.00 154.31 151.01 154.22 154.22 599,645
Dec 3, 2025 153.20 154.35 150.26 151.96 151.96 823,304
Dec 2, 2025 151.13 153.79 150.84 152.48 152.48 853,246
Dec 1, 2025 152.38 153.29 149.58 150.88 150.88 703,685
Nov 28, 2025 152.78 153.70 150.41 152.16 152.16 501,000
Nov 26, 2025 146.75 153.54 146.00 151.58 151.58 1,732,038
Nov 25, 2025 141.67 144.75 140.67 143.53 143.53 631,745
Nov 24, 2025 142.02 143.50 139.27 141.25 141.25 1,206,626
Nov 21, 2025 140.24 144.83 139.72 141.83 141.83 967,900
Nov 20, 2025 138.72 141.07 137.83 138.98 138.98 797,978
Nov 19, 2025 140.22 140.22 137.02 138.06 138.06 1,091,285
Nov 18, 2025 142.99 145.08 138.43 138.63 138.63 1,271,776
Nov 17, 2025 144.66 145.91 142.44 143.56 143.56 856,603
Nov 14, 2025 142.99 146.38 142.99 144.86 144.86 642,910
Nov 13, 2025 146.01 148.84 143.91 144.16 144.16 922,569
Nov 12, 2025 147.40 148.03 145.41 146.85 146.85 1,155,779
Nov 11, 2025 147.50 149.42 145.00 147.29 147.29 1,352,557
Nov 10, 2025 152.97 154.10 146.02 150.02 150.02 964,285
Nov 7, 2025 154.25 154.50 148.97 152.37 152.37 1,431,361
Nov 6, 2025 153.86 155.64 152.86 154.80 154.80 944,420
Nov 5, 2025 147.70 157.67 147.70 153.75 153.75 2,937,687
Nov 4, 2025 142.35 143.87 140.82 143.19 143.19 744,569
Nov 3, 2025 142.62 144.98 139.46 141.96 141.96 764,238
Oct 31, 2025 138.04 143.47 137.06 143.21 143.21 1,325,948
Oct 30, 2025 137.41 140.19 136.51 138.04 138.04 899,868
Oct 29, 2025 140.00 144.30 133.61 138.02 138.02 3,007,342
Oct 28, 2025 147.38 149.98 146.62 147.38 147.38 1,401,311
Oct 27, 2025 145.00 149.33 144.94 148.94 148.94 964,731
Oct 24, 2025 143.60 144.42 142.20 144.00 144.00 636,132
Oct 23, 2025 141.89 144.65 141.72 143.67 143.67 674,621
Oct 22, 2025 143.43 143.69 141.26 141.47 141.47 593,183
Oct 21, 2025 141.79 142.97 141.29 142.65 142.65 511,725
Oct 20, 2025 141.08 142.59 138.78 141.33 141.33 673,662
Oct 17, 2025 137.52 140.47 137.02 140.09 140.09 977,237
Oct 16, 2025 138.13 140.73 136.70 137.52 137.52 798,441
Oct 15, 2025 137.19 139.46 137.00 137.73 137.73 650,884
Oct 14, 2025 137.65 138.60 135.78 137.23 137.23 598,540
Oct 13, 2025 136.85 139.56 135.63 137.35 137.35 671,139
Oct 10, 2025 139.29 139.34 135.80 136.63 136.63 493,782
Oct 9, 2025 139.94 140.53 138.39 138.47 138.47 607,973
Oct 8, 2025 137.87 139.74 136.10 139.08 139.08 683,963
Oct 7, 2025 139.80 141.14 135.96 137.00 137.00 854,524
Oct 6, 2025 137.21 140.65 136.60 139.43 139.43 899,059
Oct 3, 2025 137.30 137.80 135.76 137.03 137.03 1,216,178
Oct 2, 2025 136.32 137.63 135.59 136.74 136.74 936,644
Oct 1, 2025 140.12 141.36 136.61 137.00 137.00 1,395,727
Sep 30, 2025 140.28 141.69 137.97 140.38 140.38 1,181,619
Sep 29, 2025 141.55 141.97 139.16 140.27 140.27 903,088
Sep 26, 2025 141.86 142.08 139.90 142.00 142.00 980,288
Sep 25, 2025 145.29 145.61 140.52 140.89 140.89 1,069,611
Sep 24, 2025 146.25 148.00 145.61 146.67 146.67 652,257
Sep 23, 2025 146.00 147.56 145.67 146.40 146.40 664,788
Sep 22, 2025 145.00 147.73 144.37 146.62 146.62 700,623

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Neurocrine Biosciences Inc Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at NBIX, per a recent SEC DEF 14A filing. We estimate that the median employee at NEUROCRINE BIOSCIENCES INC is paid $265,089.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation